来自MSN2 个月
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA
With the FDA granting a priority review to the BLA, a decision from the regulatory body is expected on July 22, 2025. Shares of REPL were up 16.9% on Jan. 21 following the announcement of the news ...
Wall Street Journal4 年
Replimune Group Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
ETF Daily News2 天
Swiss National Bank Grows Holdings in Replimune Group, Inc. (NASDAQ:REPL)
Replimune Group Stock Down 0.6 % REPL stock opened at $10.39 on Friday. The firm’s 50-day moving average is $12.67 and its two-hundred day moving average is $12.15. The company has a market ...